Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 3;104(6):1209–1220. doi: 10.3324/haematol.2018.201483

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 2. — CRBN mRNA levels of multiple myeloma (MM) cells and their correlation with sensitivity to ARV 825. (A) CRBN expression in tumor cell lines (Broad Cancer Cell Line Encyclopedia). (B) Positive correlation [correlation coefficient (R)=0.6] between CRBN mRNA expression in eight parental MM cell lines (2-^D(Ct) x 10⁵), and their sensitivity to ARV 825, n=3; P<0.001) (Left). Relative CRBN mRNA expression of isogenic lenalidomide resistant (MM1S res and KMS11 res) and isogenic wild-type (MM1S and KMS11) myeloma cells, and comparison of their sensitivity to increasing concentrations of ARV 825 [growth inhibition (MTT) of the cells]. (Right, top) MM1S and MM1S res cells and (right, bottom) shows KMS11 and KMS11 res cells, and their IC50s to ARV 825. (C and D) Levels of CRBN mRNA expression (left) and protein (right, top) from KMS11 and KMS28BM cells, and their viability in ARV 825 (right, bottom) after (C) overexpression and (D) shRNA silencing. OE: overexpression. *P≤0.01; **P≤0.001; ***P≤0.0001.